Swedish Orphan Biovitrium acquires Dova Pharma and with it Doptelet.

Swedish Orphan Biovitrum AB (publ) (Sobi) announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. by means of a tender offer. The consideration consists of an upfront payment of $27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR). The CVR entitles Dova shareholders to an additional $1.50 per share upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia (CIT) by the FDA. The upfront cash component of the offer represents a premium of 36 per cent based on Dova's most recent closing price of $ 20.19. The transaction is valued at up to $ 915 million (approximately SEK 9.0 billion) on a fully diluted basis. The acquisition of Dova provides Sobi with Doptelet (avatrombopag), a differentiated on-market product in Chronic Immune Thrombocytopenia (ITP), a well established and growing market, for Chronic Liver Disease (CLD) and an ongoing phase III trial in Chemotherapy Induced Thrombocytopenia.